{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:02:38Z","timestamp":1793700158014,"version":"4.5.1"},"reference-count":57,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R24AI24872"],"award-info":[{"award-number":["R24AI24872"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI069907"],"award-info":[{"award-number":["U01AI069907"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI069911"],"award-info":[{"award-number":["U01AI069911"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI096299"],"award-info":[{"award-number":["U01AI096299"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"],"award-info":[{"award-number":["R24AI24872 U01AI069907 U01AI069911 U01AI096299"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Since July 2019, the WHO has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients \u226516 years on or initiating treatment between January 2017 and July 2021 in 14 low- and middle-income countries where initial guidelines on DTG-based regimens for first-line ART either restricted use by WRA or had no such restrictions. We estimated the cumulative incidence of DTG uptake (CI-DTG) by sex and age group (aged 16\u201349 years vs 50+ years), stratified by patient, clinic and setting characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 177\u2009706 patients on ART during the study period, 51% were females aged 16\u201349 years, with 25% males aged 16\u201349 and 13% and 11%, respectively, females and males aged 50+. At the time of DTG-for-All, overall CI-DTG was 29.6% (95% CI 29.4% to 29.8%); it was lower among females aged 16\u201349 (16.2%; 95%\u2009CI 16.0% to 16.5%) than males (41.1%; 95%\u2009CI 40.6% to 41.5%), with no sex disparities among patients aged 50+ (females: 46.0%; males: 47.0%). While DTG uptake subsequently increased among all groups, by July 2021, it remained substantially lower among females 16\u201349 (66.4%; 95%\u2009CI 66.1% to 66.7%), compared with males 16\u201349 and older females and males (75.8% to 77.5%). Concentrated in countries where initial guidelines on DTG restricted use by WRA, disparities in DTG uptake persisted at all health system levels and in both low-income and lower-middle-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While sex-age differentials in DTG uptake narrowed after WHO\u2019s DTG-for-All recommendation, lingering disparities in uptake underscore the difficulty of policy de-implementation when new evidence emerges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-020159","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:20:31Z","timestamp":1773411631000},"page":"e020159","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8514-1958","authenticated-orcid":false,"given":"Ellen","family":"Brazier","sequence":"first","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Romo","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L","family":"Ciaranello","sequence":"additional","affiliation":[{"name":"Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Odhiambo","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Nairobi County, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Pujari","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5522","authenticated-orcid":false,"given":"Gad","family":"Murenzi","sequence":"additional","affiliation":[{"name":"School of Public Health, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda"},{"name":"Goodlife Access, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kasozi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Masaka Regional Referral Hospital, Masaka, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique Mahambu","family":"Nsonde","sequence":"additional","affiliation":[{"name":"Centre de Traitement Ambulatoire Brazzaville, Brazzaville, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Muyindike","sequence":"additional","affiliation":[{"name":"Mbarara National Referral Hospital, Mbarara, Mbarara, Uganda"},{"name":"Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vohith","family":"Khol","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Dermatology and STDs, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lelo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Kalembelembe Pediatric Hospital, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Lyamuya","sequence":"additional","affiliation":[{"name":"Care and Treatment Centre, Morogoro Regional Hospital, Morogoro, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8591-4773","authenticated-orcid":false,"given":"Man Po","family":"Lee","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Hong Kong, SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[{"name":"Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA"},{"name":"City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026031307201397000_11.3.e020159.1","unstructured":"World Health Organization (WHO) . Update of recommendations on first- and second-line antiretroviral regimens geneva. Switzerland World Health Organization; 2019. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf"},{"key":"2026031307201397000_11.3.e020159.2","unstructured":"World Health Organization . Statement on dtg. 2018."},{"key":"2026031307201397000_11.3.e020159.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"2026031307201397000_11.3.e020159.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"2026031307201397000_11.3.e020159.5","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3358"},{"key":"2026031307201397000_11.3.e020159.6","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"Phillips","year":"2019","journal-title":"Lancet HIV"},{"key":"2026031307201397000_11.3.e020159.7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(18)31641-6","article-title":"Changes to dolutegravir policy in several African countries","volume":"392","author":"Nakkazi","year":"2018","journal-title":"The Lancet"},{"key":"2026031307201397000_11.3.e020159.8","doi-asserted-by":"crossref","unstructured":"Granich R , Gupta S . HIV treatment in sub-saharan africa: did bureaucratic headwinds delay access to dolutegravir? Open Science Framework [Preprint] 2019. doi:10.31219\/osf.io\/uzg7y","DOI":"10.31219\/osf.io\/uzg7y"},{"key":"2026031307201397000_11.3.e020159.9","doi-asserted-by":"publisher","DOI":"10.7326\/M21-3037"},{"key":"2026031307201397000_11.3.e020159.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026031307201397000_11.3.e020159.11","unstructured":"IeDEA . International epidemiologic databases to evaluate aids (iedea). n.d. Available: https:\/\/www.iedea.org"},{"key":"2026031307201397000_11.3.e020159.12","doi-asserted-by":"crossref","unstructured":"Duda SN , Musick BS , Davies M-A , et al . The iedea data exchange standard: a common data model for global hiv cohort collaboration. Health Informatics [Preprint]. doi:10.1101\/2020.07.22.20159921","DOI":"10.1101\/2020.07.22.20159921"},{"key":"2026031307201397000_11.3.e020159.13","unstructured":"UNAIDS & WHO . Laws and Policies Analytics 2017-2012.Available: https:\/\/lawsandpolicies.unaids.org\/about?lan=en"},{"key":"2026031307201397000_11.3.e020159.14","unstructured":"National Center for HIV\/AIDS DaSN . Operational guidance: use of dolutegravir (dtg) for adults and adolescents in Cambodia. 2018. Available: https:\/\/www.nchads.gov.kh\/documents_post\/operational-guidance-use-of-dolutegravir-dtg-for-adults-and-adolescents-in-cambodia"},{"key":"2026031307201397000_11.3.e020159.15","unstructured":"Ministry of Health (Kenya) . Guidelines on use of antiretroviral drugs for treating and preventing hiv in Kenya. 2018. Available: https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/guidelines-use-antiretroviral-drugs-treating-and-preventing-hiv-kenya-2018"},{"key":"2026031307201397000_11.3.e020159.16","unstructured":"Ministry of Health (Uganda) . Consolidated guidelines for prevention and treatment of HIV in Uganda. 2018. Available: http:\/\/library.health.go.ug\/publications\/service-delivery-diseases-control-prevention-communicable-diseases\/hivaids\/consolidated"},{"key":"2026031307201397000_11.3.e020159.17","unstructured":"Ministry of Health (Rwanda) . Circular on changes in HIV prevention and management guidelines. 2018. Available: https:\/\/rbc.gov.rw\/fileadmin\/user_upload\/guide\/Circular"},{"key":"2026031307201397000_11.3.e020159.18","unstructured":"Ministere de la Sant\u00e9 Publique (Cameroon) . Directives nationales sur la prise en charge du VIH. 2019. Available: https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/national-guidelines-hiv-care"},{"key":"2026031307201397000_11.3.e020159.19","unstructured":"Ministry of Health (Vietnam) . Guidelines for hiv\/aids treatment and care issued together with decision no.5456\/qd-byt. 2019."},{"key":"2026031307201397000_11.3.e020159.20","unstructured":"Minist\u00e8re de la Sant\u00e9 Publique (R\u00e9publique D\u00e9mocratique du Congo) . Guide de prise en charge integr\u00e9e du vih en r\u00e9publique d\u00e9mocratique du congo (draft). 2019."},{"key":"2026031307201397000_11.3.e020159.21","unstructured":"Ministry of Health (Tanzania) . National guidelines for the management of HIV and AIDS. 2019. Available: https:\/\/hivpreventioncoalition.unaids.org\/sites\/default\/files\/attachments\/national_guidelines_for_the_management_of_hiv_and_aids_2019.pdf"},{"key":"2026031307201397000_11.3.e020159.22","unstructured":"Ministere de la Sante et de la Population (Republic of Congo) . Lignes directrices relatives \u00e0 l\u2019utilisation de m\u00e9dicaments antir\u00e9troviraux pour le traitement et la pr\u00e9vention de l\u2019infection \u00e0 vih au congo. 2019."},{"key":"2026031307201397000_11.3.e020159.23","unstructured":"Ministry of Health and Family Welfare (India) . National guidelines for HIV care and treatment. 2021. Available: https:\/\/naco.gov.in\/sites\/default\/files\/2020-21.pdf"},{"key":"2026031307201397000_11.3.e020159.24","unstructured":"Department of Health (Philippines) . Tenofovir\/lamivudine\/dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV. 2021. Available: https:\/\/hta.dost.gov.ph\/wp-content\/uploads\/2021\/09\/ES_TLD_for_HIV_approved_by_SOH.docx.pdf"},{"key":"2026031307201397000_11.3.e020159.25","unstructured":"Department of Disease Control (Thailand) . Thailand national guidelines on hiv\/aids treatment and prevention. 2021. Available: https:\/\/www.thaiaidssociety.org\/wp-content\/uploads\/2023\/03\/HIV-AIDS-Guideline-2564_2565_ED2.pdf"},{"key":"2026031307201397000_11.3.e020159.26","unstructured":"Expert panel for HIV\/AIDS and STI prevention (Indonesia) . In: Rekomendasi Panel Ahli Penanggulangan HIV\/AIDS dan IMS Hasil Rapat Daring. 2020. Available: https:\/\/hivaids-pimsindonesia.or.id"},{"key":"2026031307201397000_11.3.e020159.27","unstructured":"World Health Organization (WHO) . Women of reproductive age (15-49 years) population (thousands). 2024. Available: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/women-of-reproductive-age-(15-49-years)-population-(thousands)"},{"key":"2026031307201397000_11.3.e020159.28","unstructured":"The World Bank . World bank list of economies. 2022. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"2026031307201397000_11.3.e020159.29","first-page":"141","article-title":"An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Statist"},{"key":"2026031307201397000_11.3.e020159.30","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","article-title":"Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens","volume":"19","author":"Inzaule","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026031307201397000_11.3.e020159.31","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001845"},{"key":"2026031307201397000_11.3.e020159.32","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00499-x"},{"key":"2026031307201397000_11.3.e020159.33","doi-asserted-by":"crossref","unstructured":"Shah N , Esber A , Sean Cavanaugh J , et al . Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa. Clin Infect Dis 2022. doi:10.1093\/cid\/ciac555","DOI":"10.1093\/cid\/ciac555"},{"key":"2026031307201397000_11.3.e020159.34","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae139","article-title":"Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts","volume":"11","author":"Tiendrebeogo","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026031307201397000_11.3.e020159.35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(24)00270-5","article-title":"Is it time to revisit the recommendations for initiation of menopausal hormone therapy?","volume":"13","author":"Taylor","year":"2025","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026031307201397000_11.3.e020159.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-1111-8","article-title":"Understanding how and why de-implementation works in health and care: research protocol for a realist synthesis of evidence","volume":"8","author":"Burton","year":"2019","journal-title":"Syst Rev"},{"key":"2026031307201397000_11.3.e020159.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-019-0960-9","article-title":"Unpacking the complexities of de-implementing inappropriate health interventions","volume":"15","author":"Norton","year":"2020","journal-title":"Implement Sci"},{"key":"2026031307201397000_11.3.e020159.38","unstructured":"PEPFAR . PEPFAR 2019 country operational plan guidance for all pepfar countries. 2019. Available: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/08\/PEPFAR-Fiscal-Year-2019-Country-Operational-Plan-Guidance.pdf"},{"key":"2026031307201397000_11.3.e020159.39","unstructured":"PEPFAR . Regional operational plan (West Africa regional program): strategic direction summary. 2019. Available: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/09\/West-Africa_ROP19-Strategic-Directional-Summary_public-FINAL.pdf"},{"key":"2026031307201397000_11.3.e020159.40","unstructured":"PEPFAR . Asia region operational plan (rop 2019): strategic direction summary. 2019. Available: https:\/\/www.state.gov\/wp-content\/uploads\/2019\/09\/Asia-Regional_COP19-Strategic-Directional-Summary_public.pdf"},{"key":"2026031307201397000_11.3.e020159.41","unstructured":"de Silva J , Vallabhaneni S , Pati R , eds. Successful Transition to Tenofovir\/Lamivudine\/Dolutegravir (TLD) in PEPFAR-Supported Countries. Montreal, Canada: AIDS, 2022."},{"key":"2026031307201397000_11.3.e020159.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12961-022-00899-y","article-title":"Improving WHO\u2019s understanding of WHO guideline uptake and use in Member States: a scoping review","volume":"20","author":"Saluja","year":"2022","journal-title":"Health Res Policy Syst"},{"key":"2026031307201397000_11.3.e020159.43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jclinepi.2020.07.008","article-title":"Guidelines in Low and Middle Income Countries Paper 1: Scoping clinical practice guidelines in Chile and the Philippines","volume":"127","author":"Dans","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026031307201397000_11.3.e020159.44","doi-asserted-by":"crossref","DOI":"10.4102\/sajhivmed.v21i1.1103","article-title":"The evolution and adoption of World Health Organization policy guidelines on antiretroviral therapy initiation in sub-Saharan Africa: A scoping review","volume":"21","author":"Govere","year":"2020","journal-title":"South Afr J HIV Med"},{"key":"2026031307201397000_11.3.e020159.45","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/heapol\/czx023","article-title":"A qualitative study of the determinants of HIV guidelines implementation in two south-eastern districts of Tanzania","volume":"32","author":"Mwangome","year":"2017","journal-title":"Health Policy Plan"},{"key":"2026031307201397000_11.3.e020159.46","unstructured":"E M . Achieving 95-95-95: implications for asia and the pacific region. 2021. Available: https:\/\/www.aidsdatahub.org\/sites\/default\/files\/resource\/2021-sep5-achieving-95-95-95-hiv-treatment-forum.pdf"},{"key":"2026031307201397000_11.3.e020159.47","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1097\/QAD.0000000000004007","article-title":"Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics","volume":"38","author":"Zaniewski","year":"2024","journal-title":"AIDS"},{"key":"2026031307201397000_11.3.e020159.48","unstructured":"Medicines Patent Pool (MPP) . DOLUTEGRAVIR - adult (DTG) licence. 2014. Available: https:\/\/medicinespatentpool.org\/licence-post\/dolutegravir-adult-dtg"},{"key":"2026031307201397000_11.3.e020159.49","unstructured":"Healthcare V . Dolutegravir (Tivicay) Package Insert. Durham, NC USA: ViiV Healthcare, 2024."},{"key":"2026031307201397000_11.3.e020159.50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/25787489.2021.2003132","article-title":"Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study","volume":"22","author":"Pelchen-Matthews","year":"2021","journal-title":"HIV Res Clin Pract"},{"key":"2026031307201397000_11.3.e020159.51","doi-asserted-by":"crossref","DOI":"10.12688\/aasopenres.13107.1","article-title":"Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-na\u00efve HIV-1 Subtype C-infected patients in Botswana","volume":"3","author":"Maruapula","year":"2020","journal-title":"AAS Open Res"},{"key":"2026031307201397000_11.3.e020159.52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ebiom.2019.11.040","article-title":"HIV drug resistance testing \u2013 The quest for Point-of-Care","volume":"50","author":"Noguera-Julian","year":"2019","journal-title":"EBioMedicine"},{"key":"2026031307201397000_11.3.e020159.53","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-023-00505-3","article-title":"Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings","volume":"20","author":"Manyana","year":"2023","journal-title":"AIDS Res Ther"},{"key":"2026031307201397000_11.3.e020159.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-09991-w","article-title":"Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda","volume":"20","author":"Alhassan","year":"2020","journal-title":"BMC Public Health"},{"key":"2026031307201397000_11.3.e020159.55","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-023-02630-7","article-title":"Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV","volume":"23","author":"Chapola","year":"2023","journal-title":"BMC Womens Health"},{"key":"2026031307201397000_11.3.e020159.56","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06851-9","article-title":"Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda","volume":"21","author":"Twimukye","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026031307201397000_11.3.e020159.57","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s10461-024-04454-4","article-title":"\u201cNo One Needs to be Forced\u201d: Qualitative Insights on Competing Priorities between Antiretroviral Therapy and Reproductive Health Planning during the Dolutegravir Rollout","volume":"28","author":"Maju","year":"2024","journal-title":"AIDS Behav"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-020159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:20:54Z","timestamp":1773411654000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-020159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjgh-2025-020159"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-020159","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}